Could a Telomere-Targeting drug reboot immunotherapy in lung cancer?
Disease control
Ongoing
This study tests a new drug called THIO, which targets telomeres (parts of chromosomes), followed by the immunotherapy cemiplimab in people with advanced non-small cell lung cancer whose cancer stopped responding to initial immunotherapy. The goal is to see if this sequence can s…
Phase: PHASE2 • Sponsor: Maia Biotechnology • Aim: Disease control
Last updated May 17, 2026 07:32 UTC